Vismodegib

Generic Name
Vismodegib
Brand Names
Erivedge
Drug Type
Small Molecule
Chemical Formula
C19H14Cl2N2O3S
CAS Number
879085-55-9
Unique Ingredient Identifier
25X868M3DS
Background

Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...

Indication

用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。

Associated Conditions
Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
Associated Therapies
-
Clinical Trials
Related News

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

First Posted Date
2024-09-27
Last Posted Date
2024-09-27
Lead Sponsor
Dwight Owen
Target Recruit Count
24
Registration Number
NCT06616623
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

First Posted Date
2024-04-10
Last Posted Date
2024-10-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
35
Registration Number
NCT06357988
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Phase 2
Recruiting
Conditions
Basal Cell Carcinoma
Interventions
Drug: SP-002
Drug: Vismodegib
First Posted Date
2024-04-03
Last Posted Date
2024-05-23
Lead Sponsor
Stamford Pharmaceuticals, Inc.
Target Recruit Count
80
Registration Number
NCT06344052
Locations
🇺🇸

Research Site, Longview, Texas, United States

Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

First Posted Date
2022-09-30
Last Posted Date
2022-10-03
Lead Sponsor
University Hospital, Lille
Target Recruit Count
82
Registration Number
NCT05561634

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

First Posted Date
2022-09-13
Last Posted Date
2024-12-12
Lead Sponsor
Ronald Buckanovich
Target Recruit Count
48
Registration Number
NCT05538091
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

First Posted Date
2022-07-19
Last Posted Date
2024-05-22
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
80
Registration Number
NCT05463757
Locations
🇳🇱

UMCG, Groningen, Netherlands

🇳🇱

Radboudumc, Nijmegen, Gelderland, Netherlands

🇳🇱

Maastricht University Medical Center +, Maastricht, Limburg, Netherlands

and more 5 locations

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1
Withdrawn
Conditions
Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Interventions
Drug: Alectinib
Drug: Alpelisib
Drug: Anastrozole
Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Drug: Carboplatin
Drug: Cobimetinib
Drug: Entrectinib
Drug: Eribulin
Drug: Fulvestrant
Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Irinotecan
Drug: Letrozole
Drug: Nab-paclitaxel
Drug: Niraparib
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Vemurafenib
Drug: Vinorelbine
Drug: Vismodegib
First Posted Date
2022-02-14
Last Posted Date
2024-01-23
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT05238831

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

First Posted Date
2021-12-16
Last Posted Date
2024-07-15
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
250
Registration Number
NCT05159245
Locations
🇫🇮

Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland

🇫🇮

Kuopio University Hospital, Kuopio, Finland

🇫🇮

Oulu University Hospital OYS Cancer Center, Oulu, Finland

and more 2 locations

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

First Posted Date
2020-04-10
Last Posted Date
2022-10-26
Lead Sponsor
Ulrik Lassen
Target Recruit Count
300
Registration Number
NCT04341181
Locations
🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

and more 4 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy